CAM2038

DRUG3 trials

Sponsors

Braeburn Pharmaceuticals, Yale University

Conditions

Chronic PainModerate or Severe Opioid Use DisorderOpioid Use DisorderOpioid-use Disorder

Phase 2

A Multiple Dose Opioid Challenge Study

CompletedNCT02611752

Braeburn PharmaceuticalsModerate or Severe Opioid Use Disorder

Start: 2015-10-31End: 2016-04-30Updated: 2019-11-14

Phase II Pharmacokinetics Study of CAM2038

CompletedNCT02710526

Braeburn PharmaceuticalsChronic Pain, Opioid Use Disorder

Start: 2015-02-28End: 2017-07-03Updated: 2020-04-30

Emergency Department-Initiated Buprenorphine Validation Network Trial

CompletedNCT04225598

Yale UniversityOpioid-use Disorder

Start: 2020-07-08End: 2024-12-06Updated: 2025-01-10

Related Papers

Emergency Department–Initiated Buprenorphine for Opioid Use Disorder

JAMA2026-02-111 citations

Adaptive decision support for addiction treatment to implement initiation of buprenorphine for opioid use disorder in the emergency department: protocol for the ADAPT Multiphase Optimization Strategy trial

BMJ Open2025-02-012 citations

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal

JAMA Network Open2024-07-0825 citations

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder.

2023-08-164 citations

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder

JAMA Psychiatry2017-06-2775 citations